1. Home
  2. SNY vs HASI Comparison

SNY vs HASI Comparison

Compare SNY & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNY
  • HASI
  • Stock Information
  • Founded
  • SNY 1994
  • HASI 1981
  • Country
  • SNY France
  • HASI United States
  • Employees
  • SNY N/A
  • HASI N/A
  • Industry
  • SNY Biotechnology: Pharmaceutical Preparations
  • HASI Real Estate Investment Trusts
  • Sector
  • SNY Health Care
  • HASI Real Estate
  • Exchange
  • SNY Nasdaq
  • HASI Nasdaq
  • Market Cap
  • SNY 113.4B
  • HASI 3.5B
  • IPO Year
  • SNY N/A
  • HASI 2013
  • Fundamental
  • Price
  • SNY $46.86
  • HASI $28.11
  • Analyst Decision
  • SNY Buy
  • HASI Strong Buy
  • Analyst Count
  • SNY 4
  • HASI 6
  • Target Price
  • SNY $61.50
  • HASI $37.67
  • AVG Volume (30 Days)
  • SNY 2.7M
  • HASI 822.0K
  • Earning Date
  • SNY 10-24-2025
  • HASI 11-06-2025
  • Dividend Yield
  • SNY 3.41%
  • HASI 5.97%
  • EPS Growth
  • SNY 118.56
  • HASI N/A
  • EPS
  • SNY 8.65
  • HASI 1.59
  • Revenue
  • SNY $53,714,621,258.00
  • HASI $92,418,000.00
  • Revenue This Year
  • SNY $1.53
  • HASI $184.19
  • Revenue Next Year
  • SNY $7.06
  • HASI $13.31
  • P/E Ratio
  • SNY $5.42
  • HASI $17.72
  • Revenue Growth
  • SNY 15.65
  • HASI N/A
  • 52 Week Low
  • SNY $44.73
  • HASI $21.98
  • 52 Week High
  • SNY $60.12
  • HASI $36.56
  • Technical
  • Relative Strength Index (RSI)
  • SNY 42.29
  • HASI 52.12
  • Support Level
  • SNY $46.79
  • HASI N/A
  • Resistance Level
  • SNY $47.69
  • HASI $28.53
  • Average True Range (ATR)
  • SNY 0.67
  • HASI 0.45
  • MACD
  • SNY -0.23
  • HASI -1.06
  • Stochastic Oscillator
  • SNY 32.91
  • HASI 97.54

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: